AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 AUG 15 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Autoclaved Leishmania major (ALM) along with BCG, shows promise for protection against cutaneous leishmaniasis and should be evaluated in humans, say researchers in India, working in cooperation with the World Health Organization (WHO).
A. Misra and associates vaccinated eight monkeys with 1 mg each of ALM plus bacillus Calmette-Guerin (BCG), then challenged them intravenously 60 days later with 100 x 10(6) amastigotes. They then assessed parasite load in splenic tissue on days 45, 90 and 180.
Seven of the eight vaccinated monkeys developed infection but recovered by day 180, but the eighth monkey, which had a much higher parasite burden at day 45, died on day 130.
All four of the unvaccinated control monkeys died by day 180 postchallenge, reported Misra and coworkers ("Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG," Vaccine, 2001;19(25-26):3485-3492).
Vaccinating the monkeys caused an initial rise in antileishmania antibodies compared with the unvaccinated control group, the researchers added, a rise that later returned to normal but remained higher in the unvaccinated control group.
They noted increasing antigen-specific proliferative responses and interferon (IFN) gamma levels to the two antigens - ...
Source: HighBeam Research, Vaccine Protects Seven of Eight Monkeys From Fatal L....